Abstract:Aims: Due to its high heterogenicity and unclear etiology, there is currently no specific treatment for polycystic ovary syndrome (PCOS). Metformin, as an insulin sensitizer, combined with spironolactone, an antiandrogen medication, may exert complementary effects on PCOS. We therefore performed a meta-analysis of trials in which metformin combined with spironolactone was applied to treat PCOS to evaluate the efficacy and safety of the combination therapy. Methods: We retrieved the PubMed, Embase, Scopus, Cochrane Library, CNKI, CBM, Wangfang, and VIP databases for literatures published from their inception to December 16, 2022 on the effects of metformin combined with spironolactone in the treatment of PCOS. Inclusion criteria according to P.I.C.O.S criteria were: PCOS patients, metformin combined with spironolactone interventions, metformin alone control group, and randomized controlled trials with the following outcome data: body mass index (BMI), hirsutism score, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (TT), fasting blood glucose (FBG), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), and side effects including nausea, vomiting, diarrhea and drug withdrawal. Results: Our results revealed that metformin combined with spironolactone significantly reduced BMI and TT, but that it exerted no significant effects on hirsutism score, or on FSH or LH concentrations. Combined treatment also resulted in a significant diminution in FBG and insulin resistance using the HOMA-IR when the interventional time was greater than 6 months. In addition, the combination did not have a higher occurrence of adverse reactions than metformin alone. Conclusion: Compared with metformin alone, metformin combined with spironolactone therapy may be more effective in reducing BMI and serum androgen levels, but the combination showed no significant effect on the hirsutism score or gonadotropin hormone levels, and was not associated with an elevation in side-effects. Moreover, when the treatment course was greater than 6 months, combination therapy reduced FBG and improved insulin resistance more effectively than metformin alone. However, more research is needed to determine the most effective course of treatment. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022355515.

Effects of orlistat and metformin on metabolism and gonadal function in overweight or obese patients with polycystic ovary syndrome

Effect of Metformin on Reproductive Endocrine and Glucose and Lipid Metabolism of Polycystic Ovary Syndrome Patients with or Without Central Obesity

Pharmacologic Therapy To Induce Weight Loss In Women Who Have Obesity/Overweight With Polycystic Ovary Syndrome: A Systematic Review And Network Meta-Analysis

[Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome]

Effect of probiotics combined with metformin on improvement of menstrual and metabolic patterns in women with polycystic ovary syndrome: a randomized clinical trial

Clinical Efficacy of Orlistat in Chinese Overweight and Obese Patients with Newly Diagnosed Type 2 Diabetes

Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses

Effect of metformin on insulin levels, blood sugar, and body mass index in polycystic ovarian syndrome cases

Effects of GLP-1R agonist or co-cyprindiol, in combination with metformin, on polycystic ovary syndrome in overweight women: A Randomized Clinical Trial

[Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]

Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis

Effect of Short-Term Treatment with Metformin on Psychological Distress and Metabolic Feature in Patients with Polycystic Ovary Syndrome

Clinical observation of laparoscopic sleeve gastrectomy and metformin treatment in obese PCOS patients

Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment

Study on the Effect of Glucose Metabolism Related Indexes by Small dose of Metformin Combined with the Blood House of Blood Stasis Pill in Patients with Polycystic Ovary Syndrome

Clinical effect of estrogen combined with metformin in the treatment of adolescent polycystic ovary syndrome

Therapeutic Effect of Metformin on Patients with Polycystic Ovary Syndrome with Normal Insulin Sensitivity: A Retrospective Study

Efficacy of metformin combined with vitamin D in the treatment of polycystic ovarian syndrome: A meta-analysis

Effects of three medical nutrition therapies for weight loss on metabolic parameters and androgen level in overweight/obese patients with polycystic ovary syndrome

The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethinyloestradiol on PCOS patients

The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial